Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update

BACKGROUND: Since 2020, annual reports on the clinical development of new drug-based therapies for the neurodegenerative condition of Parkinson’s disease (PD) have been generated. These reviews have followed the progress of both “symptomatic treatments” (ST – improves/reduces symptoms of the conditi...

Descripción completa

Detalles Bibliográficos
Autores principales: McFarthing, Kevin, Buff, Susan, Rafaloff, Gary, Fiske, Brian, Mursaleen, Leah, Fuest, Rosie, Wyse, Richard K., Stott, Simon R.W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2023
Materias:
Clinical Trial Highlights
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357160/
https://www.ncbi.nlm.nih.gov/pubmed/37302040
http://dx.doi.org/10.3233/JPD-239901

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357160/
https://www.ncbi.nlm.nih.gov/pubmed/37302040
http://dx.doi.org/10.3233/JPD-239901

Ejemplares similares